The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Open accessPublished version of a preprint
Abstract
Purpose: We hypothesized that autophagy inhibition would increase response to chemotherapy in the preoperative setting for patients with pancreatic adenocarcinoma. We performed a randomized controlled trial to assess the autophagy inhibitor hydroxychloroquine in combination with gemcitabine and nab-paclitaxel. Patients and Methods: Participants with potentially resectable tumors were randomized to two cycles of nab-paclitaxel and gemcitabine (PG) alone or with hydroxychloroquine (PGH), followed by resection. The primary endpoint was histopathologic response in the resected specimen. Secondary clinical endpoints included serum CA 19-9 biomarker response and margin negative R0 resection. Exploratory endpoints included markers of autophagy, immune infiltrate, and serum cytokines. Results: Thirty-four patients in the PGH arm and 30 in the PG arm were evaluable for the primary endpoint. The PGH arm demonstrated statistically improved Evans grade histopathologic responses (P = 0.00016), compared with control. In patients with elevated CA 19-9, a return to normal was associated with improved overall and recurrence-free survival (P < 0.0001). There were no differences in serious adverse events between arms and chemotherapy dose number was equivalent. The PGH arm had greater evidence of autophagy inhibition in their resected specimens (increased SQSTM1, P = 0.027, as well as increased immune cell tumor infiltration, P = 0.033). Overall survival (P = 0.59) and relapse-free survival (P = 0.55) did not differ between the two arms. Conclusions: The addition of hydroxychloroquine to preoperative gemcitabine and nab-paclitaxel chemotherapy in patients with resectable pancreatic adenocarcinoma resulted in greater pathologic tumor response, improved serum biomarker response, and evidence of autophagy inhibition and immune activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“clinical trials have shown that hydroxychloroquine, which inhibits autophagic flux by preventing lysosomal acidification, enhances PDAC patient response to chemotherapy212,213”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott‐Schwartz, J., Yin, X., Weiss, W. A., Takebe, N., Timmer, W. C., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 912
Self-citationTranscriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., et al. (2015) · Nature · doi:10.1038/nature14587 · Cited by 799
Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
Evans, D. B. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420110083017 · Cited by 771
Guo, J. Y., Karsli-Uzunbas, G., Mathew, R., Aisner, S. C., Kamphorst, J. J., Strohecker, A. M., Chen, G., Price, S., Lu, W., Teng, X., et al. (2013) · Genes & Development · doi:10.1101/gad.219642.113 · Cited by 589
Haeno, H., Gönen, M., Davis, M. B., Herman, J. M., Iacobuzio–Donahue, C. A., & Michor, F. (2012) · Cell · doi:10.1016/j.cell.2011.11.060 · Cited by 412
Yang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0952 · Cited by 349
Breslin, T. M. (2001) · Annals of Surgical Oncology · doi:10.1245/aso.2001.8.2.123 · Cited by 310
Cited by
Sorted by citations
Items 201–233 of 233
Review Article: Efficacy and Safety of JNK Inhibitors in Cancer Therapy
Sahithi, L. S., Nuthalapati, P., Mohammed, F., Natesh, N. S., Umeza, B., Santoshi, R. D., Afzal, K. A. K., & Ghanta, M. K. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025060497 · Cited by 1
Li, H., Zhu, N., Shi, Y., Liu, Q., Gu, J., & Li, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2219062/v1 · Cited by 1
Chen, C., Pan, M., Wu, B., li, X., Chen, Z., Xu, Q., Li, X., & Lv, Q. (2020) · doi:10.22541/au.158697188.86645424
Raghavan, M., & Kaur, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737795659.793574735
Botelho, M. S., Bolfi, F., Leite, R. G. O. F., Leite, M. S. F., Banzato, L. R., Soares, L. T., Olivatti, T. O. F., Mangolim, A. S., Oliveira, F. R. K., Abbade, L. P. F., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-75518/v1
SH2 Superbinder Inhibits Autophagy of Pancreatic Cancer Cells by Blocking DDR1-Mediated SignalingPreprint
Liu, A., Hou, G., Sang, Y.-Z., Li, L., Gan, X.-C., Xu, H., & Cao, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2831216/v1
Neoadjuvant Treatment of Pancreatic Cancer
Wolff, R. A. (2023) · doi:10.1002/9781119876007.ch146
Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical Treatment and Outcomes
Chakraborty, R., Dutta, A., Baruah, B. J., Kumari, R., Sarma, P., Sharma, A., Goswami, K., Myakala, H., & Verma, A. K. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230830125213
Nakata, K., Oyama, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Zhong, P., Date, S., Luo, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3419957/v1
Precision medicine for PDAC immunotherapy
Ukwade, D., Osmani, K., Fernandez, L., Hussain, S., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00014-6
Identification and validation of autophagy-related genes in sepsis based on bioinformatics studies
Wei, D.-P., Jiang, W., Chen, C., Chen, Z.-Y., Zhou, F.-Q., Zhang, Y., & Lu, J. (2025) · Virology Journal · doi:10.1186/s12985-025-02683-0
Chauhan, N., Majumdar, A. G., Bhutia, S. K., Dey, P., Subramanian, M., & Patro, B. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.07.674530
Roos-Mattila, M., Mustonen, H. K., Vähä-Koskela, M. J. V., Boyd, S., Vainionpää, S., Hwang, R. F., Puolakkainen, P. A., Joncour, V. L., Laakkonen, P. M., & Seppänen, H. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.04.686484
Ding, K., Tian, H., Li, L., Wang, Z., Liu, S., Ding, N., Nice, E. C., Huang, C., Bao, J., Gao, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25687523
Dysregulated autophagy at the nexus of type 2 diabetes mellitus and pancreatic cancer pathogenesis
Li, L., Chen, Y., Wang, S., Du, W., Lao, T., Chen, F., Yao, G., Chen, W., Li, X., Liu, C., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1735726
Autophagy in cancer-associated fibroblasts: its role in gastrointestinal cancers
Kuppala, V., Chintapudi, H., Gopalaiah, K., Nagaraju, G. P., & El‐Rayes, B. F. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02626-5
Cao, Y., Cheng, C., Yin, Y., Yee, S. N., Zheng, Y., Mahapatra, S., Paturu, R., Coleski, A., VanAken, S. M., Yang, F., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102695 · Cited by 1
Song, D., Tang, H., You, T. T., Ying, J., Bai, C., Sun, Z., Han, Q., & Zhao, R. C. (2026) · Stem Cells and Development · doi:10.1177/15473287261442512
Zhang, Y., Gobin, T. L., Huang, Z., Miao, B., Kurilov, R., Sun, H., Tjaden, C., Heger, U., Hackert, T., Hinz, U., et al. (2026) · Cell Death and Disease · doi:10.21203/rs.3.rs-9358319/v1
A review of autophagy in the pancreas: normal physiology and pathophysiology
Piper, M., & Kinsey, C. G. (2026) · Autophagy Reports · doi:10.1080/27694127.2026.2665907
Metabolic plasticity in the pancreatic cancer metastatic cascade
Zhu, B., Guo, Y., & Lu, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189622 · Cited by 1
An, B., Gao, Z., Chen, S., Meng, L., Zhang, C., Song, K., Cui, H., Yan, L., & Fang, Z. (2026) · Advanced Science · doi:10.1002/advs.76165
Roach, M. K., Degan, S. E., DeLiberty, J. M., Pita, L. M., Pieper, N. L., 杨闰英, Taylor, K. E., Schechter, E. G., Robb, R. N., Pierobon, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.28.734981
Chauhan, N., Majumdar, A. G., Bhutia, S. K., Dey, P., Subramanian, M., & Patro, B. S. (2026) · Autophagy · doi:10.1080/15548627.2026.2693263
Targeting lysosome-dependent cell death in cancer: towards therapeutic strategies
Li, Y., Feng, J., Dong, X., Yuan, Z., Zheng, L.-L., Zhang, L., & Wang, L. (2026) · Biomarker Research · doi:10.1186/s40364-026-00969-1 · Cited by 1
Kim, J., Ylaya, K., Chung, E. J., Jun, S., Hong, S., & Chung, J. (2026) · Life · doi:10.3390/life16071193
Henderson, E. A., Łukomski, S., & Boone, B. A. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261470694
Self-citationMultiomics Identification of Novel Diagnostic Biomarkers and Precise Therapeutic Targets for Sepsis
Gu, M., Chen, X., Tang, N., & Hu, X. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/3132904
Zheng, Y., Cheng, C., Cao, Y., Cruz, G., Zhang, Y., Paturu, R., Mahapatra, S., Hu, J., Mannan, R., Karabürk, H., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.07.003
Apoptosis and Autophagy Modulators in Cancer Therapeutics
Patel, V., Islam, M. S., & Kotnis, A. L. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_21
Autophagy inhibition in pancreatic cancer: hope or hype?
Guilbaud, E., Cukierman, E., Astsaturov, I. A., & Galluzzi, L. (2026) · Autophagy Reports · doi:10.1080/27694127.2026.2721748
Liu, X., Ye, Z., Wang, L., Chi, Y., Chu, T., Liu, Z., Yu, S., Yang, H., Yin, X., Zhang, J., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1977031
Metadata
- Authors
- Zeh, H. J., Bahary, N., Boone, B. A., Singhi, A. D., Miller-Ocuin, J. L., Normolle, D. P., Zureikat, A. H., Hogg, M. E., Bartlett, D. L., Lee, K. K., Tsung, A., Marsh, J. W., Murthy, P., Tang, D., Seiser, N., Amaravadi, R. K., Espina, V., Liotta, L., & Lotze, M. T.
- Affiliations
- University of Pittsburgh (US)
- St Vincent Medical Center (US)
- University of Pennsylvania (US)
- George Mason University (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2020-07-01
- Volume
- 26
- Issue
- 13
- Pages
- 3126-3134
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC8086597
- OpenAlex
- W3010751808
- Cited by
- 233
- References
- 34
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 33 · 2023: 43 · 2022: 36 · 2021: 38 · 2020: 18
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (1R01 CA181450, R01GM115366, R01CA206012)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, autophagy inhibition, hydroxychloroquine, gemcitabine, nab-paclitaxel, neoadjuvant chemotherapy, resectable pancreatic cancer, CA19-9, p62, tumor-infiltrating immune cells, R0 resection, overall survival, relapse-free survival
- MeSH terms
- Gemcitabine, Adult, Aged, Aged, 80 and over, Albumins, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Deoxycytidine, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Preoperative Care, Recurrence, Survival Analysis, Treatment Outcome, Paclitaxel, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
